Picture of Effector Therapeutics logo

EFTR — Effector Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

eFFECTOR Therapeutics rises on positive interim data for breast cancer drug

** Shares of drug developer eFFECTOR Therapeutics Inc
 EFTR.O  rise 62.80% to $0.86 premarket, among top pct. gainers
across U.S. exchanges
    ** Announced positive interim data from a mid-stage study
evaluating combination therapy of its zotatifin in patients with
a type of breast cancer
    ** Says partial responses observed in 5 of 19 evaluable
patients treated with 0.07 mg/kg dose of zotatifin combined with
AstraZeneca Plc's  AZN.L  fulvestrant and Eli Lilly and Co's
 LLY.N  abemaciclib
     ** Adds partial response observed in 1 of 3 patients
treated with 0.1 mg/kg dose of combined with fulvestrant
    ** Both combinations were generally well tolerated - EFTR
    ** Plans to report data from the completed dose escalation
in H2 
    ** Up to last close, stock up ~23% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))

Recent news on Effector Therapeutics

See all news